Dr. Reddy's Laboratories has launched Vigabatrin tablets, an antiepileptic drug, in the US market. The company has launched the drug in the American market after receiving approval from the US Food and Drug Administration (USFDA). This product has been designated as a Competitive Generic Therapy (CGT) by the FDA.
With a CGT designation, the company has a 180-day CGT exclusivity to market this product. The company's product is a generic version of Sabril tablets. As per the IMS Health data, the Sabril brand and its generics had sales of around $141 million for the most recent 12 months ending December last year.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: